Pear Therapeutics Presents Data at ASAM Virtual 2020 Program Demonstrating High Satisfaction and Engagement for reSET® and reSET-O® in Treating Substance Use Disorder and Opioid Use Disorder
BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. presented results today from an open-label study that evaluated participant engagement and satisfaction with reSET® and reSET-O®, prescription digital therapeutics (PDTs) that deliver evidence-based disease treatment through cognitive behavioral therapy, fluency training and contingency management for substance use disorder (SUD) and opioid use disorder (OUD) via mobile device. Study participants showed…
Details